Rankings
▼
Calendar
ZTS
Zoetis Inc.
$52B
Q3 2017 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$1.3B
+8.5% YoY
Gross Profit
$889M
66.0% margin
Operating Income
$465M
34.5% margin
Net Income
$298M
22.1% margin
EPS (Diluted)
$0.61
QoQ Revenue Growth
+6.1%
Cash Flow
Operating Cash Flow
$439M
Free Cash Flow
$391M
Stock-Based Comp.
$11M
Balance Sheet
Total Assets
$9.3B
Total Liabilities
$7.3B
Stockholders' Equity
$2.0B
Cash & Equivalents
$2.0B
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$1.3B
$1.2B
+8.5%
Gross Profit
$889M
$812M
+9.5%
Operating Income
$465M
$377M
+23.3%
Net Income
$298M
$239M
+24.7%
Revenue Segments
Dogs and Cats
$546M
41%
Cattle
$424M
32%
Swine
$147M
11%
Poultry
$119M
9%
Fish
$39M
3%
Horses
$34M
3%
Sheep and Other
$25M
2%
← FY 2017
All Quarters
Q4 2017 →
ZTS Q3 2017 Earnings — Zoetis Inc. Revenue & Financial Results | Market Cap Arena